GlobeNewswire

ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC

Share

LYON, France and CAMBRIDGE, Mass., June 26, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first patient has been enrolled in its Phase 2 clinical trial, named TRYbeCA2,  evaluating its lead product candidate eryaspase for the treatment of first line triple negative breast cancer (TNBC).

Following the positive Phase 2 results with eryaspase in second-line metastatic pancreatic cancer, ERYTECH selected  triple-negative breast cancer as the next indication to expand the potential use of eryaspase in solid tumors. TNBC is an aggressive and metabolically active form of breast cancer with high rates of symptomatic metastases. A Phase 2/3 clinical trial in first-line metastatic TNBC, named TRYbeCA2, was designed and the Phase 2 part of the trial was launched in Spain, Belgium, Hungary and the United Kingdom. The trial is evaluating eryaspase in combination with gemcitabine and carboplatin chemotherapy, compared to chemotherapy alone. Target enrollment in the Phase 2 part of the trial is approximately 64 patients. The primary endpoint is objective response rate.  

“Most women with triple negative breast cancer have very limited treatment options.” stated Iman El Hariry, MD, PhD, Chief Medical Officer of ERYTECH. “Based on accumulated preclinical research of targeting metabolic pathways in TNBC, we believe that the combination of eryaspase with chemotherapy may offer a potential treatment option to these patients. The trial reinforces our strategy to develop medicines that may benefit patients with challenging diseases.”

“I am very pleased that eryaspase, an innovative and promising approach, is evaluated in this Phase 2/3 study in TNBC patients and hopeful that it may provide a novel treatment modality for this highly unmet medical need," commented Prof. Awada, Head of the Medical Oncology Clinic at Jules Bordet Cancer Institute Brussels, Belgium.

About Triple-Negative Breast Cancer (TNBC)

Breast cancer is the most commonly diagnosed cancer in women globally with nearly 2.0 million new cases diagnosed annually1. It is estimated that approximately 800,000 women each year are diagnosed with breast cancer in the United States and Europe in aggregate1, 2. Approximately 10-20% of breast cancers are TNBC, a form of breast cancer that lacks expression of estrogen receptor (ER), progesterone receptor (PR) and does not overexpress HER23.  TNBC is associated with a poorer prognosis when compared to other breast cancer subtypes.  As commonly utilized hormone therapy and HER2 targeting agents are not treatment options for women with TNBC, there is significant unmet need for novel therapeutic approaches in this subtype of breast cancer.

1 World Health Organization (International Agency for Research on Cancer), Globocan 2018
2 Cancer Facts and Figures, 2018 (American Cancer Society)
3 Yam C et al., The Oncologist, September 2017

About ERYTECH: www.erytech.com

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs.

ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is also developing erymethionase, which consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. 

ERYTECH produces product candidates at its GMP-approved manufacturing site in Lyon, France, and at the American Red Cross in Philadelphia, USA. A large-scale GMP manufacturing facility has recently opened for operations in Princeton, New Jersey, USA and will begin manufacturing later this year.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

CONTACTS   
   
ERYTECH    
Eric Soyer
CFO & COO
NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations
   
+33 4 78 74 44 38
investors@erytech.com
+33 1 44 71 98 52
erytech@newcap.eu

Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy, expansion of manufacturing capacity and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the potential of ERYTECH’s product pipeline, its clinical development of eryaspase, and the timing of ERYTECH’s preclinical studies and clinical trials and announcements of data from those studies and trials. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2018 Document de Référence filed with the AMF on March 29, 2019 and in the Company’s Annual Report on Form 20-F filed with the SEC on March 29, 2019 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Hiab secures its biggest ever commercial order18.7.2019 13:30:00 CESTPress release

CARGOTEC CORPORATION, PRESS RELEASE, 18 JULY 2019 AT 2:30 PM EEST Hiab, part of Cargotec, has signed a record-breaking agreement to supply MOFFETT M8 55.4 NX truck mounted forklifts with five year ProCare Essential service contracts and equipped with HiConnect for each unit, with one of the largest home improvement chains in the USA. The total order value is over EUR 60 million. In the second quarter, EUR 31 million was booked in the order entry with EUR 29 million booked for the third quarter. This is Hiab’s largest ever commercial deal and ProCare contract agreement, as well as the biggest single order for the Truck Mounted Forklift Business Line. Deliveries are expected to start in the third quarter 2019 and continue until May 2020. When complete, the customer will have updated a significant portion of their fleet with new connected equipment. This will enable them to collect data from a substantial part of the fleet to improve productivity, safety and get service alerts based on ac

Sweden to issue green bonds by 202018.7.2019 13:10:00 CESTPress release

The Swedish National Debt Office was tasked today by the Government with carrying out an issue of green bonds in 2020 at the latest. The first step will be to set up a framework for the green bonds, which will fund budget expenditure on sustainable investments and projects. "We are fully committed to implementing this assignment in an effective and transparent way. The effects of the climate and environmental measures that are funded by the State’s green bonds should be easy for investors to follow and evaluate", says Debt Office Director General Hans Lindblad. The assignment includes working together with the Government Offices to set up the ‘green framework’, which includes defining the expenditure items in the budget that will be funded by the green bonds. The Debt Office shall also analyze how to carry out the issue in an optimal way within the management of central government debt. The issuance volume shall, according to the assignment, comply with the objective of the debt manage

Riksgälden ska ge ut gröna obligationer senast 202018.7.2019 13:10:00 CESTPressemelding

Riksgälden har fått i uppdrag av regeringen att senast under 2020 genomföra en emission av statliga gröna obligationer, det vill säga obligationer som finansierar utgiftsposter i statens budget som går till hållbara investeringar och projekt. Nu inleds arbetet med att ta fram ett ramverk för de statliga gröna obligationerna. – Vi tar oss an uppdraget med full kraft och inleder nu vårt förberedande arbete för att genomföra det på ett effektivt och transparent sätt. Som investerare ska man tydligt kunna följa och utvärdera de miljö- och klimatsatsningar som finansierats med de statliga gröna obligationerna, säger riksgäldsdirektör Hans Lindblad. Uppdraget från regeringen omfattar att samverka med Regeringskansliet för att utarbeta det så kallade gröna ramverket. I ramverket ska det bland annat definieras vilka utgiftsposter i statens budget som ska finansieras genom de gröna obligationerna. Riksgälden ska också analysera hur emissionen ska genomföras på bästa sätt inom ramen för statssku

Cargotec’s January–June 2019 half year financial report: Good progress in Hiab and Kalmar18.7.2019 13:00:00 CESTPress release

CARGOTEC CORPORATION, 2019 HALF YEAR FINANCIAL REPORT, 18 JULY 2019 AT 2.00 PM EEST Cargotec’s January–June 2019 half year financial report: Good progress in Hiab and Kalmar Strong profit growth in Kalmar Record high operating profit in Hiab Weak result in MacGregor April–June 2019 in brief: Operating profit increased Orders received decreased by 11 percent and totalled EUR 872 (981) million. Comparison period included a single order for Kalmar worth around EUR 80 million. Order book amounted to EUR 2,072 (31 Dec 2018: 1,995) million at the end of the period. Sales increased by 12 percent and totalled EUR 911 (816) million. Service sales increased by 5 percent and totalled EUR 259 (247) million. Service and software sales represented 33 (34) percent of consolidated sales. Operating profit was EUR 53.0 (21.3) million, representing 5.8 (2.6) percent of sales. Comparable operating profit increased by 12 percent and amounted to EUR 64.3 (57.2) million, representing 7.1 (7.0) percent of sal

Orange Belgium launches Love Duo, the mobile and fixed internet pack intended for cord-cutters18.7.2019 08:52:00 CESTPress release

Press release Brussels, 18 July 2019 Orange Belgium launches Love Duo, the mobile and fixed internet pack intended for cord-cutters In keeping with its bold challenger role, Orange Belgium is once again offering consumers a choice. Henceforth they will only pay for the services they really need. Love Duo is a mobile subscription à la carte, to which is added the fixed internet access for packs costing between 42 and 64 euros, depending on the desired volumes of voice and data. After launching the first unlimited mobile subscription in Belgium, Orange Belgium went and did it again with the first unlimited convergent offer. Since its launch, the Love offer has succeeded in attracting over 200,000 customers, upending the convergent offers market in its wake. Orange Belgium is now attacking one of the main nodal points of the Belgian telecom market by launching Love Duo, a pack including only a mobile subscription and ultrafast and unlimited fixed internet. An offer intended first and fore

Statkraft AS: Resultat for andre kvartal 201918.7.2019 08:00:00 CESTPressemelding

Markedsaktiviteter og høyere kraftproduksjon løftet kvartalsresultatet (Oslo, 18. juli 2019) Statkraft oppnådde et underliggende driftsresultat på 2619 millioner kroner i andre kvartal. Dette var en økning på 1190 millioner kroner fra tilsvarende periode i fjor. Økningen skyldtes hovedsakelig forbedret resultat fra Markedsoperasjoner og høyere kraftproduksjon. Gjennomsnittlig nordisk systempris i kvartalet var 35,6 EUR/MWh, en nedgang på 9 prosent sammenlignet med samme kvartal i 2018. Statkrafts totale kraftproduksjon ble 12,3 TWh, en økning på 0,9 TWh. Resultat etter skatt endte på 2123 millioner kroner. Dette er en økning på 1852 millioner kroner. I første halvår oppnådde Statkraft et underliggende driftsresultat på 9049 millioner kroner, en forbedring på 1659 millioner kroner sammenlignet med samme periode i 2018. Hoveddriverne for forbedringen var høyere bidrag fra handelsaktivitetene i segmentet Markedsoperasjoner. Resultat etter skatt for første halvår endte på 6874 million kron